

## **Universal Health Coverage:** a people-centred approach






### When one size does not fit all






#### When one size does not fit all





# Vaccine product innovations can help to break coverage and equity plateaus





Improve safety
Increase Health Impact
Improve coverage and equity









Reduce procurement cost Decrease delivery cost



## Total Systems Effectiveness identifies the most effective vaccine product innovations



### WHO full public health value proposition (FPHVP):

focusing on maximising public health value from a *population/societal* perspective.



TSE informs the optimal product preferences by aligning priority vaccine attributes with country needs.

Preferred product characteristics















### Total Systems Effectiveness identifies the most effective vaccine product innovations



TSE promotes a change in the product development paradigm, so that country demand informs product development

Traditional approach:



PQ – pre-qualification
PPC – preferred product
characteristics (guidance from
WHO for a specific pathogen)
TPP – target product profile
(produced by product developers
for a specific product)

TSE approach:



TSE should create a 'pull' for new products that meet LMIC preferences ......and reduce the timeline between licensure and uptake